Clinical Trial Update: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical study evaluating duvortuxizumab plus ibrutinib in lymphomas has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Duvortuxizumab (duvortuxizumab)
• Ibrutinib (ibrutinib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse | Phase 1 | Status: WITHDRAWN